SCHEMBL3485915

SCHEMBL3485915

CCOC(=O)C(C)(C)c1ccc2[nH]c(-c3cccc(C(F)(F)F)c3)cc2c1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP26A1 O43174 1/20 0.46
CYP26B1 Q9NR63 1/20 0.46
MEN1 O00255 1/20 0.44
MAPT P10636 1/20 0.44
KMT2A Q03164 1/20 0.44
PTGDR2 Q9Y5Y4 2/20 0.43
PIN1 Q13526 1/20 0.41
KDM4E B2RXH2 2/20 0.41
ALDH1A1 P00352 1/20 0.41
GAA P10253 1/20 0.41
HPGD P15428 1/20 0.41
CDC7 O00311 1/20 0.40
GRIN1 Q05586 1/20 0.40
GRIN2B Q13224 1/20 0.40
CNR2 P34972 1/20 0.40
KCNQ2 O43526 1/20 0.39
XPO1 O14980 1/20 0.39
TUBB4A P04350 1/20 0.39
TUBB P07437 1/20 0.39
TUBA3C P0DPH7 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3485725 0.90 PTGDR2 (0.43) CYP26A1CYP26B1KMT2APTGDR2KDM4E
SCHEMBL3485248 0.88 CNR2 (0.44) CYP26A1CYP26B1PTGDR2KDM4EALDH1A1
SCHEMBL3485210 0.87 KCNH2 (0.41) CYP26A1CYP26B1MEN1MAPTKMT2A
SCHEMBL3485857 0.87 PPARG (0.50) CYP26A1CYP26B1MEN1MAPTKMT2A
SCHEMBL8165963 0.87 PTGDR2 (0.41) CYP26A1CYP26B1PTGDR2KDM4EALDH1A1
SCHEMBL3485207 0.83 PTGDR2 (0.39) CYP26A1CYP26B1MEN1KMT2APTGDR2
SCHEMBL3485770 0.83 KCNQ2 (0.42) PTGDR2KDM4EALDH1A1HPGDCNR2
SCHEMBL3485495 0.83 KCNQ2 (0.47) MEN1MAPTKMT2APTGDR2KDM4E
SCHEMBL3485486 0.82 PTGDR2 (0.41) CYP26A1CYP26B1MAPTPTGDR2GAA
SCHEMBL3485556 0.82 CNR2 (0.52) MEN1MAPTKMT2AKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK SHARP & DOHME CORP. 2010-04-08 US disclosed
WO-2008133867-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS MERCK & CO., INC. (US) 2008-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087446-A1 2-SUBSTITUTED INDOLE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS TRPV1, CACNA1S, TRPV2 CYP26A1 3672/4885CYP26B1 3123/4885MEN1 1585/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.